Moderna Past Earnings Performance
Past criteria checks 2/6
Moderna has been growing earnings at an average annual rate of 76.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 78.4% per year. Moderna's return on equity is 43.7%, and it has net margins of 43.4%.
Key information
76.3%
Earnings growth rate
76.4%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 78.4% |
| Return on equity | 43.7% |
| Net Margin | 43.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Moderna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 19,263 | 8,362 | 1,132 | 0 |
| 30 Sep 22 | 21,390 | 11,765 | 958 | 0 |
| 30 Jun 22 | 22,995 | 14,055 | 848 | 0 |
| 31 Mar 22 | 22,600 | 14,638 | 758 | 0 |
| 31 Dec 21 | 18,471 | 12,202 | 567 | 0 |
| 30 Sep 21 | 11,831 | 7,061 | 445 | 0 |
| 30 Jun 21 | 7,019 | 3,495 | 325 | 0 |
| 31 Mar 21 | 2,732 | 598 | 241 | 0 |
| 31 Dec 20 | 803 | -747 | 188 | 0 |
| 30 Sep 20 | 246 | -597 | 135 | 0 |
| 30 Jun 20 | 106 | -488 | 115 | 0 |
| 31 Mar 20 | 52 | -505 | 106 | 0 |
| 31 Dec 19 | 60 | -514 | 110 | 0 |
| 30 Sep 19 | 82 | -535 | 122 | 0 |
| 30 Jun 19 | 106 | -499 | 112 | 0 |
| 31 Mar 19 | 122 | -459 | 105 | 0 |
| 31 Dec 18 | 135 | -402 | 94 | 0 |
| 30 Sep 18 | 192 | -299 | 72 | 0 |
| 30 Jun 18 | 192 | -280 | 70 | 0 |
| 31 Mar 18 | 199 | -266 | 65 | 0 |
| 31 Dec 17 | 206 | -270 | 65 | 0 |
| 31 Dec 16 | 108 | -230 | 57 | 0 |
Quality Earnings: 0QF has a high level of non-cash earnings.
Growing Profit Margin: 0QF's current net profit margins (43.4%) are lower than last year (66.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0QF has become profitable over the past 5 years, growing earnings by 76.3% per year.
Accelerating Growth: 0QF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0QF had negative earnings growth (-31.5%) over the past year, making it difficult to compare to the Biotechs industry average (-26.8%).
Return on Equity
High ROE: 0QF's Return on Equity (43.7%) is considered outstanding.